Analyst Notes Podcast: PD-(L)1-based combination regimens in renal cell carcinoma (RCC) – KOLs speak out

FirstWord's Duncan Emerton - Senior Director of Syndicated Insights and Analysis - and Sarah Harris - Senior Analyst - discuss some of the key findings from a new KOL Insight: Renal Cell Carcinoma report


New Report - Renal Cell Carcinoma: KOL Insight

The treatment of advanced RCC has been transformed in recent years as VEGF, TKI and mTOR inhibitors have taken centre stage. KOLs now argue that the first-line treatment of advanced RCC is on the cusp of a second wave of change. At the forefront is a multitude of immunotherapy-based combination regimens that look set to transform first-line therapy, including Keytruda/Inlyta, Bavencio/Inlyta, Tecentriq/Avastin, Cabometyx/Opdivo±Yervoy and Keytruda/Lenvima. The adjuvant setting is also set to become a key battleground with multiple agents in Phase III trials. What will be the critical factors for success as the rapidly evolving treatment armamentarium leads to ever more complex decision making for oncologists? In this report six US and six EU KOLs offer their candid insights on ten marketed therapies and five pipeline drugs.

Click here for more information

To read more Analyst Notes articles, click here.

Reference Articles